checkAd
    Startseite > Aktien > Oncternal Therapeutics > Nachrichten
    Oncternal Therapeutics Aktie
    8,2600
     
    USD
    -7,81 %
    -0,7000 USD
    Letzter Kurs 03.05.24 Nasdaq
    8,1000
     
    USD
    600 STK
    Geldkurs 03.05.24
    8,8900
     
    USD
    200 STK
    Briefkurs 03.05.24
    ISIN: US68236P2065 · WKN: A40063 · SYM: ONCT · USA

    Neueste Nachrichten

    Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
    08.01.24 · globenewswire · Oncternal Therapeutics
    Oncternal Therapeutics Announces Reverse Stock Split
    04.01.24 · globenewswire · Oncternal Therapeutics
    Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
    02.01.24 · globenewswire · Oncternal Therapeutics
    Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma
    26.12.23 · globenewswire · Oncternal Therapeutics
    Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
    09.11.23 · globenewswire · Oncternal Therapeutics
    Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
    26.10.23 · globenewswire · Oncternal Therapeutics
    Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board
    25.10.23 · globenewswire · Oncternal Therapeutics
    Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer
    05.10.23 · globenewswire · Oncternal Therapeutics
    Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board
    07.09.23 · globenewswire · Oncternal Therapeutics
    Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
    10.08.23 · globenewswire · Oncternal Therapeutics
    Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results
    03.08.23 · globenewswire · Oncternal Therapeutics
    Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
    30.06.23 · globenewswire · Oncternal Therapeutics